Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism

HJ. Kim, O. Aktas, KR. Patterson, S. Korff, A. Kunchok, JL. Bennett, BG. Weinshenker, F. Paul, HP. Hartung, D. Cimbora, MA. Smith, N. Mittereder, WA. Rees, D. She, BAC. Cree

. 2023 ; 10 (12) : 2413-2420. [pub] 20231007

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000440

Grantová podpora
MedImmune/AstraZeneca

Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes CD19+ B-cells, is approved to treat aquaporin 4 (AQP4) IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is afucosylated and engineered for enhanced affinity to Fc receptor III-A (FCGR3A) receptors on natural killer cells to maximize antibody-dependent cellular cytotoxicity. Previously, the F allele polymorphism at amino acid 158 of the FCGR3A gene (F158) was shown to decrease IgG-binding affinity and reduce rituximab (anti-CD20) efficacy for NMOSD attack prevention. In contrast, our current findings from inebilizumab-treated NMOSD patients indicate similar clinical outcomes between those with F158 and V158 allele genotypes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000440
003      
CZ-PrNML
005      
20240213093202.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/acn3.51911 $2 doi
035    __
$a (PubMed)37804003
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kim, Ho Jin $u Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, South Korea $1 https://orcid.org/0000000286728419
245    10
$a Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism / $c HJ. Kim, O. Aktas, KR. Patterson, S. Korff, A. Kunchok, JL. Bennett, BG. Weinshenker, F. Paul, HP. Hartung, D. Cimbora, MA. Smith, N. Mittereder, WA. Rees, D. She, BAC. Cree
520    9_
$a Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes CD19+ B-cells, is approved to treat aquaporin 4 (AQP4) IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is afucosylated and engineered for enhanced affinity to Fc receptor III-A (FCGR3A) receptors on natural killer cells to maximize antibody-dependent cellular cytotoxicity. Previously, the F allele polymorphism at amino acid 158 of the FCGR3A gene (F158) was shown to decrease IgG-binding affinity and reduce rituximab (anti-CD20) efficacy for NMOSD attack prevention. In contrast, our current findings from inebilizumab-treated NMOSD patients indicate similar clinical outcomes between those with F158 and V158 allele genotypes.
650    _2
$a lidé $7 D006801
650    12
$a neuromyelitis optica $x farmakoterapie $x genetika $7 D009471
650    _2
$a akvaporin 4 $x genetika $7 D051401
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    _2
$a imunoglobulin G $7 D007074
650    _2
$a receptory IgG $x genetika $7 D017452
655    _2
$a časopisecké články $7 D016428
700    1_
$a Aktas, Orhan $u Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
700    1_
$a Patterson, Kristina R $u Horizon Therapeutics, Illinois, Deerfield, USA
700    1_
$a Korff, Schaun $u Horizon Therapeutics, Illinois, Deerfield, USA
700    1_
$a Kunchok, Amy $u Department of Neurology, Mellen Center for Multiple Sclerosis, Cleveland Clinic, Ohio, Cleveland, USA
700    1_
$a Bennett, Jeffrey L $u Department of Neurology, Programs in Neuroscience and Immunology, University of Colorado School of Medicine, Anschutz Medical Campus, Colorado, Aurora, USA
700    1_
$a Weinshenker, Brian G $u Department of Neurology, University of Virginia, Virginia, Charlottesville, USA
700    1_
$a Paul, Friedemann $u Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité, Universitätsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany $1 https://orcid.org/0000000263780070
700    1_
$a Hartung, Hans-Peter $u Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany $u Brain and Mind Centre, University of Sydney, New South Wales, Sydney, Australia $u Department of Neurology, Medical University Vienna, Vienna, Austria $u Department of Neurology, Palacky University in Olomouc, Olomouc, Czech Republic
700    1_
$a Cimbora, Daniel $u Horizon Therapeutics, Illinois, Deerfield, USA
700    1_
$a Smith, Michael A $u Horizon Therapeutics, Illinois, Deerfield, USA
700    1_
$a Mittereder, Nanette $u Horizon Therapeutics, Illinois, Deerfield, USA
700    1_
$a Rees, William A $u Horizon Therapeutics, Illinois, Deerfield, USA
700    1_
$a She, Dewei $u Horizon Therapeutics, Illinois, Deerfield, USA
700    1_
$a Cree, Bruce A C $u Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, California, San Francisco, USA $1 https://orcid.org/0000000176892533
773    0_
$w MED00189500 $t Annals of clinical and translational neurology $x 2328-9503 $g Roč. 10, č. 12 (2023), s. 2413-2420
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37804003 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093159 $b ABA008
999    __
$a ok $b bmc $g 2049232 $s 1210134
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 10 $c 12 $d 2413-2420 $e 20231007 $i 2328-9503 $m Annals of clinical and translational neurology $n Ann Clin Transl Neurol $x MED00189500
GRA    __
$p MedImmune/AstraZeneca
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace